Valbiotis Shares Surge 11% Following European Vote on Red Yeast Rice
Valbiotis shares are soaring in mid-session trading, continuing the momentum triggered by the European vote on monacolins from red yeast rice. The session is marked by a significant technical breakthrough in a Parisian market that is otherwise trending downward.
European Vote on Monacolins Reignites Interest in Valbiotis' Positioning
Valbiotis shares jumped 11.21% to €1.19 at midday, while the CAC 40 is down 0.29% and the SBF 120 is down 0.23%. The movement comes the day after the EU member states voted in favor of a draft regulation aiming to ban monacolins derived from red yeast rice in dietary supplements. The company highlights its product ValbiotisPRO Cholesterol, formulated without monacoline K or red yeast rice, which directly aligns its offering with the European regulatory trajectory on cardiometabolic prevention. Today's rise brings the weekly performance to 13.33% and the gain over three months to nearly 16%.
Breakthrough of Resistance at €1.21 Followed by a Dip Below the Threshold
The stock broke through its resistance at €1.21 during the session, reaching a high of €1.25, before falling back below this level (last price at €1.19). This foray beyond the major technical area reflects the buying strength triggered by the potential regulatory evolution, although the breakout has not yet been consolidated. The price is significantly above its three moving averages, with a 15.5% gap from the MM20 (€1.03) and over 41% from the MM200 (€0.84), indicating a strong underlying bullish trend. The RSI at 53 remains in the neutral zone, leaving room before a potential overbought signal. The ability of the price to reestablish above €1.21 is the technical element to watch in the coming sessions.
